Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorenzo Gerratana

Showing results (81-90 of 127) with videos related to

Pageof 13
Sort By:
Breast Cancer Research and Treatment|September 2, 2021
Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and ChinaXiaoran Liu, Andrew A Davis, Feng Xie, et al.
Breast (Edinburgh, Scotland)|April 3, 2021
First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world studyDebora Basile, Lorenzo Gerratana, Carla Corvaja, et al.
JCO Precision Oncology|June 17, 2021
Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast CancerLorenzo Gerratana, Andrew A Davis, Qiang Zhang, et al.
JCO Precision Oncology|June 30, 2022
Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's ExperienceLorenzo Gerratana, Michael Movarek, Firas Wehbe, et al.
Clinical Nutrition (Edinburgh, Scotland)|June 18, 2020
Prognostic role of visceral fat for overall survival in metastatic colorectal cancer: A pilot studyDebora Basile, Michele Bartoletti, Maurizio Polano, et al.
Breast Cancer Research : BCR|October 2, 2023
Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysisLorenzo Gerratana, Andrew A Davis, Marko Velimirovic, et al.
Breast (Edinburgh, Scotland)|February 6, 2026
Epigenetic and fragment-based profiling across CDK4/6 inhibitors in first-line HR+/HER2- metastatic breast cancer. An ancillary analysis of the MAGNETIC.1 studyClaudia Noto, Lorenzo Foffano, Fabiola Giudici, et al.
JAMA Network Open|February 26, 2025
Racial Differences in ctDNA Profiles, Targeted Therapy Use, and Outcomes in Metastatic Breast CancerEmily L Podany, Lorenzo Foffano, Lorenzo Gerratana, et al.
The Oncologist|March 24, 2020
The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte-to-Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal CancerDebora Basile, Silvio Ken Garattini, Carla Corvaja, et al.
NPJ Breast Cancer|December 18, 2024
Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancerLinda Cucciniello, Eva Blondeaux, Claudia Bighin, et al.
Pageof 13

Showing results (81-90 of 127) with videos related to

Sort By:
Pageof 13
Breast Cancer Research and Treatment|September 2, 2021
Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and ChinaXiaoran Liu, Andrew A Davis, Feng Xie, et al.
Breast (Edinburgh, Scotland)|April 3, 2021
First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world studyDebora Basile, Lorenzo Gerratana, Carla Corvaja, et al.
JCO Precision Oncology|June 17, 2021
Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast CancerLorenzo Gerratana, Andrew A Davis, Qiang Zhang, et al.
JCO Precision Oncology|June 30, 2022
Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's ExperienceLorenzo Gerratana, Michael Movarek, Firas Wehbe, et al.
Clinical Nutrition (Edinburgh, Scotland)|June 18, 2020
Prognostic role of visceral fat for overall survival in metastatic colorectal cancer: A pilot studyDebora Basile, Michele Bartoletti, Maurizio Polano, et al.
Breast Cancer Research : BCR|October 2, 2023
Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysisLorenzo Gerratana, Andrew A Davis, Marko Velimirovic, et al.
Breast (Edinburgh, Scotland)|February 6, 2026
Epigenetic and fragment-based profiling across CDK4/6 inhibitors in first-line HR+/HER2- metastatic breast cancer. An ancillary analysis of the MAGNETIC.1 studyClaudia Noto, Lorenzo Foffano, Fabiola Giudici, et al.
JAMA Network Open|February 26, 2025
Racial Differences in ctDNA Profiles, Targeted Therapy Use, and Outcomes in Metastatic Breast CancerEmily L Podany, Lorenzo Foffano, Lorenzo Gerratana, et al.
The Oncologist|March 24, 2020
The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte-to-Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal CancerDebora Basile, Silvio Ken Garattini, Carla Corvaja, et al.
NPJ Breast Cancer|December 18, 2024
Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancerLinda Cucciniello, Eva Blondeaux, Claudia Bighin, et al.
Pageof 13